Multiple sclerosis (MS) is one of the most common inflammatory and degenerative autoimmune diseases of the central nervous system with considerable heterogeneity in all aspects, including response to therapy. A number of disease modifying drugs, including traditional first line agents such as, interferon-beta (IFN-β) and glatiramer acetate (GA) are available for disease management. However, a considerable number of patients fail to achieve adequate response at therapeutic doses of IFN-β or GA. This variability in response to treatment has prompted the search for prognostic markers in order to personalize and optimize therapy so as to treat MS more efficiently. This review will summarize the existing literature examining the pharmacogenomics of IFN-β and GA response in MS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.autrev.2013.10.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Public Interest in Multiple Sclerosis and Its Treatment Measures in the United States: A Google Trends Analysis.
Cureus
November 2024
Department of Dermatology, Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri-Chinchwad, IND.
Introduction Multiple sclerosis (MS) afflicts over 2.8 million individuals worldwide and is a leading cause of neurological impairment in young adults. This study investigates the public interest in MS and its treatment options in the United States over the past decade, utilizing Google Trends data.
View Article and Find Full Text PDFAutoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences.
Degener Neurol Neuromuscul Dis
December 2024
Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, Germany.
Purpose: Multiple sclerosis (MS) is a neurological disorder affecting almost 2.8 million people globally, approximately 80-85% of whom have the relapsing-remitting form of the disease (RRMS). There are several autoinjectors available for the administration of injectable disease-modifying therapies for the treatment of MS.
View Article and Find Full Text PDFEffect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.
Eur J Neurol
January 2025
Multiple Sclerosis Center, Binaghi Hospital, Cagliari, Italy.
Background: The study aims to examine the age and disability levels at diagnosis in people with multiple sclerosis (PwMS), with and without autoimmune comorbidities (AC), and the effect of AC on NEDA-3 status and to characterize AC associated with MS, comparing also therapeutic approaches between MS patients with and without other AC.
Methods: This population-based, multicentric study enrolled patients with relapsing-remitting MS (RRMS) with AC (AC group) or without AC (reference group) from 14 MS centers. Demographical, clinical features, treatment information, MRI activity, EDSS, and no evidence of disease activity (NEDA-3) status were assessed at T36 (enrollment time) and T0 (36 months prior).
Identification of the most cost-saving disease-modifying therapies and factors affecting the budget in the pharmacotherapy of multiple sclerosis: a systematic review.
Eur J Clin Pharmacol
December 2024
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Multiple sclerosis (MS) is an immune-mediated disease that has a considerable health-related quality of life interference. Various disease-modifying therapies (DMTs) in MS management have been approved by the Food and Drug Administration or are currently used off-label. DMTs aim to slow down the progression of MS and decrease the frequency of relapses.
View Article and Find Full Text PDFSlow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis.
Neurol Int
November 2024
Webb-Waring Center, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12850 E Montview Boulevard, Aurora, CO 80045, USA.
Article Synopsis
- - Glatiramer Acetate (GA) is a common treatment for multiple sclerosis but requires frequent injections, and its effectiveness can vary due to inconsistent batch quality.
- - An alternative treatment, KGYY, targets the CD40 receptor and shows improved results in an animal model compared to GA, especially when formulated as slow-release particles.
- - Both GA and KGYY benefit from slow-release formulations, but KGYY exhibits more consistent effectiveness across different batches, making it a promising option for MS treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!